New drugs for mental disorders?
The general acceptance of the term 'psychopharmacology' dates from the early 1950s, when the introduction of several new drugs heralded what was widely regarded as a revolutionary step in the treatment of mental disorders. High hopes were raised by the arrival of a stream of novel compoundsthe phenothiazines, the rauwolfia alkaloids, the butyrophenones, the psychotomimetics, the benzodiazepines and lithium, to mention only the best-known. From the outset it was evident that while their impact on psychiatric practice was considerable, the precise nature of their therapeutic action was more controversialnowhere more so than in the debate on the reasons for the coincident fall in the resident population ofmental hospitals. Two leading authorities of the day summed up the polarities of outlook. According to Willi Mayer-Gross, 'hospital administrative reforms would be crying in the wilderness if the so-called tranquillising drugs had not appeared".
By contrast, for Sir Aubrey Lewis: 'if we had to choose between abandoning the use of the new drugs and abandoning the industrial rehabilitation centres and other facilities available to us there would be no hesitation about the choice; the drugs would go'2.
Notwithstanding these disputes, by the late 1960s the mass of clinical and laboratory findings had become substantial enough to constitute the basis of a subdiscipline of clinical psychopharmacology, defined in its first textbook as 'a loose federation of disciplines bound together by a common interest in psychotropic drugs'3. Even then, however, it was apparent that much of the work was empirical and, significantly, that the flow of new drugs was slowing up. In the early 1970s, in a volume entitled Search for New Drugs, Irwin concluded: 'The time is long overdue to reorient and redirect psychopharmacology from its present trial-and-error empiricism toward a more rational approach'4.
Over the past 15 years much effort and a great deal of money have been poured into the search for new psychotropic agents. In the process much has been learnt about drug action and the functions of the central nervous system, but the yield of therapeutically active substances has remained disappointingly small. This situation was discussed in some detail at a meeting of the Section of Psychiatry in March 1986 devoted to the question of 'New drugs for mental diseases?', and three of the papers presented on that occasion are published in this issue of the JRSM(pp [406] [407] [408] [409] [410] [411] [412] [413] [414] [415] [416] [417] . All three are from prominent investigators working within the pharmaceutical industry, but they reflect a marked divergence in outlook. Pinning his flag to advances in the neurosciences, Dr Stahl concludes that 'the future for the development of new drugs for mental diseases has never looked brighter'. Dr Joyce, at the other extreme, maintains that 'Not only is it possible that we do not need more existing information about existing drugs, but it is even possible that we do not need any more drugs'.
The underlying basis for this division was illuminated by the spectrum of opinions expressed during the subsequent discussion. The more pertinent of these comments speak for themselves and may be quoted verbatim. 'It is unlikely that we will find rational therapies unless we experiment on patients with new chemical entities, in a hypothesis-oriented environment'; '... the increase in regulatory control has made it progressively harder and harder to study new drugs in man and has had something to do with our decreasing success in finding new compounds'; 'the regulating authorities are the nut in the nutcrackers'; 'we need computer linkage with records, so that anybody on a particular treatment can be monitored and followed up'; 'the double-blind controlled trial only answers a very specific question, but it answers it well and we should not devalue it merely because we are getting a restricted answer'; 'the methodology of a large majority of clinical trials is defective'; 'if drug companies cannot get their drugs tested it is their own fault because they are putting too much of their resources into the me-too drugs'; 'it is becoming too expensive to fool around with innovative research'; 'because ofthe growing spate oflawsuits individual doctors are increasingly reluctant to participate in clinical trials'; 'the public is antiscientific and seems to prefer less rational forms of treatment'.
Where does the clinician of today figure in this kaleidoscopic picture? Some continue to see mental disorders in essentially biological terms and to regard psychotropic drugs as potentially or actually curative; others prefer to underline the multifactorial nature of mental illness, to assess drug effects as primarily symptomatic and to emphasize the non-biological factors in therapy. Few of them would dispense with pharmacotherapy, but most would probably view it as one element in a therapeutic programme designed to take account of the psychosocial as well as the somatic aspects of illness, and would agree that more effective compounds would be welcome.
The role of clinicians in the process remains crucial. Though chance or serendipity has often appeared to play a central part in the discovery of most psychotropic agents, Roland Kuhn, the psychiatrist who was largely responsible for identifying the antidepressant action of imipramine, has pointed out that his initial observations depended essentially on the elaboration of a particular clinical disease picture which made it possible to choose those patients who are responsive to the drug from among the great mass of mentally ill patients under his Lippincott, 1970:205-17 Routine use of beta-blockers following myocardial infarction: a note of dissent
The best treatment for the survivors of myocardial infarction is still uncertain. Two main strategies have been tried. First, investigations such as a predischarge exercise test have been used in an attempt to identify a group of patients at high risk of a subsequent cardiac event"2. Once such patients are identified, therapeutic endeavours can be concentrated on them. The benefit of surgical intervention in such a high-risk group is currently being assessed in the European post-infarction coronary bypass study. The second strategy is to attempt to treat all survivors with a single agent so that any at high risk will thereby receive treatmnent. In this regard there has been much interest in the use of beta-blockers commencing at about the time patients leave hospital, and two studies have shown benefit from their use at this time. The earlier one, from the Norwegian Multicenter Study Group, showed that over a 33-month follow-up period in a group of survivors treated with timolol, the probability of death was reduced by 39.3% when compared with a similar group who received placebo. The later study, the Beta-blocker Heart Attack Trial (BHAT)4, followed a similar protocol but used propranolol as the trial drug. This showed a smaller but nevertheless impressive reduction in mortality, 26%, over the same follow-up period. This group went further than the former as they recommended the use of propranolol for 'at least three years in patients with no contraindications to beta-blockade who have had a recent MI'. Although impressive in terms of reduction in mortality, a different picture emerges if survival is considered. One-year survival for those treated with timolol was 93.2% and with propranolol 96.3%; the corresponding survival rates for those receiving placebo were 89.3% and 94%. Thus the average oneyear survival for those treated with beta-blockade was 94.8% whereas in those receiving placebo it was 91.7%, a difference of only 3%. In other words, even without active treatment, about 92 of every 100 patients discharged from hospital following myocardial infarction would be alive one year later. Treating all 100 with a beta-blocker would only increase survival by 3.
If a policy of routine treatment of patients is to be recommended, it is worth considering the likely effect on national figures. Epidemiological data are provided by the government-funded Office of Population Censuses and Surveys. One of their studies is the Hospital In-patient Enquiry, which is a 1 in 10 sample of hospital discharges and deaths in NHS acute hospitals in England and Wales. Patients are classifid by diagnosis. The sum of discharges and deaths gives the number of admissions. In 1981 there were 100 360 hospital admissions for acute myocardial infarction; 75 240 were discharged5'6. This gives a disappointingly high overall hospital mortality of 25%. Extrapolating from the results of the two studies discussed above3 4, some 69 000 of these patients would be expected to be alive one year later if none was treated with beta-blockers whereas if all were so treated about 71300 would be alivea potential saving of 2300 lives. This compares with a total national infarction mortality of 107 0007 and suggests a potential reduction of total national infarction mortality of 2.1%.
When the cost of routine treatment is considered, we find that the cost of one year's treatment for one patient with timolol (Blockadren 10 mg twice daily) is £77.53 whereas using propranolol (Inderal 80mg three times daily) it is £48.188. For all 75 240 patients the cost would be £5 833 060 using timolol, or £3 625 060 if propranolol were used. These costs are based on the basic prices in Mims and do not take into account any discounts; on the other hand, they do not include dispensing costs.
Unfortunately the potential saving of life is likely to be less. Many patients have contraindications to beta-blockers that are readily apparent, the main ones being respiratory diseases such as chronic bronchitis or asthma and left ventricular failure. Both the studies quoted3'4 estimated that 18% of survivors of myocardial infarction had contraindications to beta-blockade.
Assuming that the risk of death in patients with and without a contraindication to beta-blockade is the same, then at best 1900 lives might be saved in the first year if all suitable survivors of infarction were treated with beta-blockers. The number would almost certainly be reduced by patients developing side effects requiring withdrawal of the beta-blockers. In the real world outside the confines of a clinical trial, however, it is possible that a number of patients with abnormalities such as first degree atrioventricular block or who are on the brink ofcardiac failure would be started on beta-blockers. This might well result in an increase in the morbidity and mortality from complete atrioventricular block -and left ventricular failure. Further, it is worrying that the routine use of beta-blockers might niask the development of postinfarction angina, which could indicate the-need for 0141-0768/87/ 070402-02/$02.00/0 i 1987 The Royal Society of Medicine
